Prostate Cancer - Results from #20

Repeatability of quantitative MR fingerprinting for T1 and T2 measurements of metastatic bone in prostate cancer patients. November 13, 2024

Tumor regression after neoadjuvant hormonal therapy in high risk prostate cancer: pathological outcomes from a randomized phase II trial. November 13, 2024

Significant Effect of Carbon-Ion Radiation Therapy Combined With Androgen Deprivation on Biochemical Recurrence Rates in High-Risk Prostate Cancer Patients: A Two-Center Controlled Trial Compare With X-Ray External Beam Radiation Therapy. November 13, 2024

Evaluating the Role of Ultrasound in Prostate Cancer trial - phase 1: Early experience of micro-ultrasound in the United Kingdom. November 13, 2024

Optimizing radiomics for prostate cancer diagnosis: feature selection strategies, machine learning classifiers, and MRI sequences. November 13, 2024

Use of Placebo in Urologic Oncology Randomized Controlled Trials. November 13, 2024

Update on PSMA-based Prostate Cancer Imaging. November 13, 2024

Progression-directed Therapy in Oligoprogressive Castration-resistant Prostate Cancer: Final Results from the Prospective, Single-arm, Phase 2 MEDCARE Trial. November 13, 2024

Preclinical Characterization of ARX517, a Site-specific Stable PSMA-Targeted Antibody Drug Conjugate for Treatment of Metastatic Castration-Resistant Prostate Cancer. November 13, 2024

A Randomized Controlled Trial of Gamification to Increase Physical Activity Among Black and Hispanic Breast and Prostate Cancer Survivors: Rationale and Design of the ALLSTAR Clinical Trial. November 12, 2024

Multi-task Bayesian model combining FDG-PET/CT imaging and clinical data for interpretable high-grade prostate cancer prognosis. November 12, 2024

Patients' anxieties and fears: a comparison between transrectal prostate biopsy and prostate MRI. November 12, 2024

Prostate cancer theragnostics biomarkers: An update. November 12, 2024

Prognostic role of prostate specific antigen kinetics in primary high volume metastatic hormonal sensitive prostate cancer treated with novel hormonal therapy agents. November 12, 2024

Overtreatment of Prostate Cancer Among Men With Limited Longevity in the Active Surveillance Era November 11, 2024

Clarity and Nucleus RadioPharma Sign Master Services Agreement and Cu-67 SAR-bisPSMA Clinical Supply Agreement November 11, 2024

Efficacy and Predictive Factors Analysis of Androgen Deprivation Plus Novel Hormone Therapy as Neoadjuvant Treatment for High-Risk Prostate Cancer. November 11, 2024

Management of de novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) and the role of Radiotherapy: A Consensus by the Italian Association of Radiotherapy and Clinical Oncology (AIRO). November 11, 2024

Commercial prices and their influence on urology practices: Prostate cancer care among men with Medicare. November 11, 2024

Plain language review: the safety of relugolix combination therapy for advanced prostate cancer. November 11, 2024

Page 2 of 1438